Objective: We aimed to identify patients with clinical Stage IA lung adenocarcinoma who are at high risk for distant recurrence to preoperatively organize treatment strategies. Methods: We analyzed correlations between preoperative clinical factors and the incidence of distant recurrence in 609 patients with clinical Stage IA lung adenocarcinoma that had been completely resected at four institutions. We excluded 24 patients with only locoregional recurrence and analyzed data from 585 patients. Results: Distant recurrence after complete resection was identified in 34 patients during a median follow-up period of 41.4 months. Multivariate Cox analysis identified solid tumor size on high-resolution computed tomography and the maximum standardized uptake value on F-18-fluorodeoxyglucose positron emission tomography/computed tomography as independent predictors for distant recurrence-free survival. Receiver operating characteristic analyses showed that solid tumor size ≥1.7 cm and the maximum standardized uptake value ≥3.3 were optimal criteria with which to detect patients at high risk for distant recurrence. In fact, 3-year distant recurrence rates were higher in patients who met the criteria for high risk (n = 85) than those who did not (n = 500) (28.1% vs. 3.7%; P < 0.001). A similar trend was also found in patients with pathological node negative. Conclusions: Solid tumor size on high-resolution computed tomography and the maximum standardized uptake value on F-18-fluorodeoxyglucose positron emission tomography/computed tomography were clinical predictors of distant recurrence among patients with clinical Stage IA lung adenocarcinoma. Our findings might be useful to determine personalized therapeutic strategies including systemic therapy.
Introduction
Advances in radiography such as high-resolution computed tomography (HRCT) and the prevalent practice of low-dose helical CT for cancer screening have increased the rates of detecting small nonsmall cell lung cancers (NSCLC), especially adenocarcinoma (1) . Opportunities to treat patients with early stage lung adenocarcinoma have increased, and radical surgery plays a key role in such treatment. Complete resection of Stage IA lung adenocarcinoma should lead to a good prognosis. However, complete resection does not always prevent distant recurrence. Such patients might suffer from potential systemic disease. Indeed, systemic therapy has priority over surgery when patients have mediastinal lymph node involvement that is considered systemic disease (2) and such patients often undergo preoperative systemic therapy (3) . In addition, patients with potentially systemic diseases indicated by postoperative lymph node involvement generally receive adjuvant chemotherapy. Preand postoperative systemic therapy would be useful for patients who are at risk for distant recurrence, including those with Stage IA lung adenocarcinoma. However, clinical predictors of distant recurrence have not yet been determined. This study aimed to identify patients with clinical Stage IA lung adenocarcinoma who are at high risk for distant recurrence based on preoperative clinical factors collected from a prospective database of medical records.
Patients and methods

Patients
We enrolled 609 patients with clinical Stage IA lung adenocarcinoma who were admitted to Hiroshima University, Kanagawa Cancer Center, the Cancer Institute Hospital or Hyogo Cancer Center between 1 October 2005 and 31 December 2010. All patients were assessed using HRCT and F-18-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) and then tumors were completely resected. The patients were staged according to the 7th edition of the TNM Classification of Malignant Tumors (4). Mediastinoscopy and endobronchial ultrasonography were not routine procedures because HRCT revealed no enlargement of the mediastinal or hilar lymph nodes and FDG-PET showed no accumulation in these lymph nodes in any of the patients. Radical segmentectomy with hilar and mediastinal lymph node dissection was allowed for mixed ground grass opacity (GGO) tumors. If intraoperative frozen sections revealed lymph node involvement, the procedure was converted to standard lobectomy. Wedge resection was allowed for pure GGO tumors that were regarded as node negative and noninvasive. All other types of adenocarcinoma were treated by standard lobectomy. None of the patients received preoperative chemotherapy or radiotherapy and patients with incompletely resected or multiple tumors were not included in the database. We defined locoregional recurrence as stumps, regional lymph nodes and pleural recurrence. Multiple lung metastases were included and solitary lung nodules with a possibility of second primary cancer were excluded. Patients with simultaneous distant and locoregional recurrence were included and 24 patients with only locoregional recurrence were excluded. Data from 585 patients were finally analyzed in this retrospective, multicenter study. The ethics review boards at each institution approved this study and waived the requirement for informed consent from the patients because the study comprised a retrospective review of medical records from a prospective database.
High-resolution CT
Chest images were acquired using 16-row multidetector CT equipment (independently of subsequent FDG-PET/CT assessments) under the following parameters: 120 kVp; 200 mA; section thickness, 1-2 mm; resolution, 512 × 512 pixels; scanning duration, 0.5-1.0 seconds; a high spatial reconstruction algorithm with a 20-cm field of view and window settings of 40 and 400 (mediastinum) and −600 and 1600 HU (lung). We defined GGO as a hazy increase in lung attenuation that did not obscure underlying vascular marks. The size of solid tumors was defined as the maximum dimension of the solid component in lung windows after excluding the GGO component (5).
FDG-PET/CT
Blood glucose was measured after a 4-hour fast to confirm ≤ 150 mg/dl and then the patients were intravenously injected with 74-370 MBq/kg of FDG. Those with blood glucose values >150 mg/ dl during PET/CT image acquisition were excluded. The integrated three-dimensional PET/CT scanners used at the four institutions comprised the Discovery ST (GE Healthcare, Little Chalfont, UK), the Aquiduo (Toshiba Medical Systems Corporation, Tochigi, Japan) or the Biograph Sensation 16 (Siemens Healthcare, Erlangen, Germany). Unenhanced CT images of 2-to 4-mm thick sections that matched the PET images from the head to the pelvic floor were acquired from each patient using a standard protocol. Immediately after CT, PET covered the identical axial field of view over periods of 2-4 minutes per table position depending on the health status of the patient and scanner performance. All PET images with a 50-cm field of view were reconstructed with iterative algorithms and CT-derived attenuation correction. Variations in standardized uptake values (SUVs) among institutions were minimized using a NEMA NU2-2001 anthropomorphic body phantom (Data Spectrum Corporation, Hillsborough, NC, USA). A calibration factor was determined by dividing the actual SUV by the gauged mean SUV of the phantom background to decrease inter-institutional SUV inconsistencies, and the final SUV is referred to as the revised SUVmax (6). Adjusting the inter-institutional SUV variation in this manner narrowed the range from 0.89-1.24 to 0.97-1.18 when the SUVmax ratio was expressed as the SUVmax of one institute relative to that of the control institute. The original SUVmax values were determined by radiologists at each institution.
Statistical analysis
Data are presented as numbers (in percentage) or as median values unless otherwise stated. Predictors of distant recurrence-free survival (RFS) were determined using univariate analysis with Cox proportional hazards models that included the preoperative clinical factors of age, sex, serum carcinoembryonic antigen (CEA) level, whole tumor size, solid tumor size and SUVmax. Serum CEA levels ≥5.0 ng/ml were defined as CEA positive. Independent predictors of distant RFS were determined using multivariate Cox analyses. Receiver operating characteristic (ROC) curves of solid tumor size and SUVmax were generated to determine the criteria required to predict high risk of distant recurrence. Frequencies were compared using the χ 2 test for categorical variables, and small samples were analyzed using Fisher's exact test. Distant RFS was defined as elapsed time from the date of surgery until the first event (distant recurrence or death from any cause) or the last follow-up. Overall survival (OS) was also defined as elapsed time from the date of surgery until death from any cause or the last follow-up. The duration of distant RFS or OS was analyzed using the Kaplan-Meier method and differences in RFS or OS were assessed using the logrank test. All data were statistically analyzed using SPSS software version 10.5 (SPSS Inc., Chicago, IL, USA).
Results Table 1 summarizes the characteristics of the 585 patients whose data were analyzed in this study. The patients were followed up for a median of 41.4 months after surgery, and the median size of whole and solid tumor size on HRCT and median SUVmax were 2.0 cm, 1.1 cm and 1.54, respectively. Lymphatic, vascular and pleural invasion was evident in 74 (12.6%), 90 (15.4%) and 56 (9.6%) patients, respectively, and lymph nodes were involved in 34 (5.8%). Distant recurrence was identified in 34 patients after complete resection. Tables 1 and 2 show the characteristics and initial distant recurrence sites of patients who experienced distant recurrence. Possible predictors of distant RFS were also investigated using univariate and multivariate analyses (Tables 3 and 4) . Whole tumor size, solid tumor size and SUVmax were significant predictors in univariate analyses. Multivariate analyses identified solid tumor size and SUVmax as significant predictors, and whole tumor size was not an independent predictor of distant RFS. We generated ROC curves to determine the cutoff values of solid tumor size and SUVmax for predicting distant recurrence (Figure 1 ). The optimal cutoff values determined using the Youden index for solid tumor size and SUVmax were 1.7 cm (sensitivity 79.4%, specificity 75.3%) and 3.3 for (sensitivity 64.7%, specificity 82.2%), respectively. We then defined patients with solid tumor size ≥ 1.7 cm and SUVmax ≥ 3.3 as being at high risk for distant recurrence. Table 5 shows the characteristics of patients who met the criteria for being at high risk of distant recurrence (high risk; n = 85) or not (low risk; n = 500). The high-risk group tended to have lymphatic, vascular, or pleural or lymph node involvement. The 3-year distant recurrence rates were significantly higher in this group (28.1% vs. 3.7%, P < 0.001). Three-year distant RFS rates significantly differed between patients at low and high risk (95.4% vs. 73.7%; P < 0.001; Figure 2A ). Three-year OS rates also significantly differed between the two groups (96.7% vs. 88.4%, P < 0.001; Figure 2B ).
Three-year distant RFS and OS rates also significantly differed between patients at low and high risk who were negative for pathological nodes (n = 551) when these criteria applied (96.5% vs. 74.2%; P < 0.001; Figure 3A ; 97.5% vs. 86.1%, P < 0.001; Figure 3B , respectively).
Discussion
We aimed to identify patients with clinical Stage IA lung adenocarcinoma who were at high risk for distant recurrence. The results of multivariate analyses indicated that solid tumor size on HRCT and SUVmax on FDG-PET/CT were independent predictors of distant RFS.
Although several investigators have described predictors of recurrence after complete resection in patients with early stage NSCLC, almost all of these studies simultaneously investigated preand postoperative factors (7, 8) . We investigated only preoperative factors in this study. Therefore, our findings allowed preoperative predictions of patients at high risk of distant recurrence.
SUVmax on FDG-PET/CT is reportedly a useful diagnostic choice for patients with lung cancer (9) (10) (11) (12) . We also previously found that SUVmax could help to predict the malignant grade of lung adenocarcinoma with regard to pathological invasiveness (6) . However, some authors found up to variation in SUV quantitation between different institutions (13) . To resolve this problem, we revised SUVmax based on outcomes from an anthropomorphic body phantom in this study.
We previously found that solid tumor size, which is the maximum dimension of the solid component in the lung windows after excluding the GGO component on HRCT, had higher predictive value than whole tumor size for pathological invasiveness and RFS (5) . Solid tumor size on HRCT combined with SUVmax on FDG-PET/CT can predict patients who are negative for pathological nodes (14) . These findings support our previous results.
Patients with Stage IA lung adenocarcinoma are considered to have limited disease. Although a meta-analysis has shown that tegafur-uracil significantly improves the survival of some patients with Stage IA NSCLC (lung adenocarcinomas >2 cm) (15), platinumbased adjuvant chemotherapy does not benefit patients with Stage IA NSCLC (16) . Few studies support the notion that preoperative systemic therapy during early stage NSCLC is beneficial (17) (18) (19) . Thus, the selection of patients suitable for systemic therapy is important. Indications for adjuvant chemotherapy in general practice are determined according to pathological findings. However, the clinical issue is that patients who developed distant recurrence did not always have nodal involvement.
However, HRCT and FDG-PET/CT can reflect tumor aggressiveness. Patients who met our proposed criteria of solid tumor size ≥ 1.7 cm, SUVmax ≥ 3.3 tended towards pathological invasiveness and distant recurrence was more frequent in this group. Moreover, SUVmax and solid tumor size could also stratify the survival of node-negative patients. We stratified patients with clinical Stage IA lung adenocarcinoma as being at high or low risk of distant recurrence based on the preoperative findings, and this was useful for personalizing therapeutic strategies such as the timing of systemic therapies and surgical procedures. Although adjuvant chemotherapy rather than preoperative therapy is presently recommended for patients with node-positive NSCLC, preoperative therapy might also be effective against early stage NSCLC in patients who are at high risk for distant recurrence. The advantages of preoperative over postoperative systemic therapy comprises earlier and thus more effective treatment, clinically and pathologically definable therapeutic sensitivity (3) and a higher ratio of patients who achieved planned chemotherapy (20) .
Moreover, postoperative systemic chemotherapy could also be considered if surgery is sufficiently early. Of course, the findings of pathological examination were available in this situation, but our findings also were useful for determining various personalized therapeutic strategies. The selection of the surgical procedure could be important considering the systemic treatment. Sublobar resection reduces postoperative complications (21) , while preserving postoperative lung function (22) and quality of life (23) . These advantages could lead to better compliance with postoperative systemic therapy. Although lobectomy is recommended standard procedure, segmentectomy would be also possible standard procedure for lung cancer with tumor size ≤2.0 cm depending on the results of the randomized controlled trial of the current observation (24) .
There are some limitations in this study. We identified patients group at high risk for distant recurrence by multivariate analysis and showed that patients in high risk group had poor distant RFS in same data set. So, validation study should be done with another data set. The retrospective nature of the analysis is also a limitation of this study, and we do not have concrete data showing that systemic therapy actually confers a measureable benefit upon patients with early stage NSCLC. Therefore, prospective studies are required to evaluate the effects of systemic therapy on Stage IA lung adenocarcinoma in patients who are at high risk for distant recurrence.
In conclusion, solid tumor size on HRCT and SUVmax on FDG-PET/CT are useful for predicting distant recurrence among patients with clinical Stage IA lung adenocarcinoma. Pre-or postoperative systemic chemotherapy is thought to be important for patients who are at high risk for distant recurrence, and our findings will help to determine various personalized therapeutic strategies including surgical procedure and timing of systemic therapy. Figure 2 . Recurrence-free (RFS) and overall (OS) survival curves for patients based on meeting criteria for solid tumor size and maximum standardized uptake value (SUVmax) that predict high risk of distant recurrence. (A) Three-year RFS rates are 95.4% and 73.7% for patients at low (solid tumor size < 1.7 cm or SUVmax < 3.3) and high (solid tumor size ≥ 1.7 cm and SUVmax ≥ 3.3) risk of recurrence, respectively (P < 0.001). (B) Three-year OS rates for patients at low and high risk are 96.7% and 88.4%, respectively (P < 0.001).
